Q3 2026 Harvard Bioscience, Inc. Earnings Conference Call - HARVARD BIOSCIENCE INC

Explicit Guidance:

• FY2026 Revenue: Reaffirmed growth of 3% to 5% year-over-year.
• FY2026 Adjusted Gross Margin: Target range of 57% to 59%.
• FY2026 Adjusted EBITDA: Guidance lowered from 6%–10% growth to -1% to 4% growth, attributed to product mix shifts toward lower-margin legacy products and increased China/distribution sales.
• Q4 2026 Revenue: Guidance set between $23.7 million and $25.5 million (midpoint $24.6 million), implying mid-single-digit year-over-year growth.
• Q4 2026 Adjusted Gross Margin: Target range of 59% to 61%.
• Q4 2026 Adjusted EBITDA: Guidance set between $3.8 million and $4.2 million (midpoint implies 5% growth).
• FY2027 EBITDA: Projected to benefit from manufacturing consolidation savings, with expectations for gross margins to reach the 60% range in 2027.
• Capex/Savings: Project Viking expected to generate $3 million in cost savings in 2027 and $4 million annually thereafter.

Business-Segment Outlook:

• New Product Innovation (NPI): Expects to expand contribution beyond current 11% of total revenue; organoid and fluidics products showing double-digit momentum.
• Preclinical Platforms: Telemetry expected to grow mid-single digits year-to-date; respiratory and inhalation products continue strong double-digit growth.
• China Operations: Revenue grew 31% in Q3; all three BTX electroporation product lines fully localized and shipping; additional product lines planned for localization in 2027 to drive revenue and margin improvement.
• Distribution Channels: Fisher Scientific North America sales have more than doubled year-to-date; distribution partner growth remains a key driver.
• Academic Sector: Current demand remains weak (contributing to EMEA decline); however, 2027 cash generation improvement is anticipated if academic funding recovers, representing a potential upside tailwind.
• CRO/Biopharma: Continued strong demand from CRO customers driven by externalization trends; biopharma growth remains positive.

Market and Competitive Outlook:

• Industry Trends: Preclinical drug candidate pipelines expanding in anticipation of the 2030 patent cliff; industry forecasts project a 7% increase in clinical trial starts over coming years.
• Competitive Position: BTX electroporation technology competing with Thermo Fisher, Lonza, and MaxSight; management does not quantify market share shifts but notes global growth.
• Product Launches: GMP/bioproduction version of electroporation equipment expected to fully launch by mid-year 2027, entering the production market.
• Recurring Revenue: Recurring revenue stable at approximately 54% of total.

Macro / Industry Outlook:

• Economic/Funding Environment: Acknowledges European academic weakness as a current headwind; U.S. and European academic funding recovery is slower than anticipated but expected to be a tailwind if conditions improve.
• Political Impact: Management does not incorporate potential increases in NIH/academic spending following recent U.S. elections into current guidance, noting potential upside if favorable policy changes occur.
• Currency: Europe revenue was 3% lower on a constant currency basis.
• Rates/Debt: No near-term principal obligations on debt; amortization begins late December 2027, facility matures December 2029.

Strategic Initiatives:

• Project Viking (Manufacturing Consolidation): On track for completion in Q1 2027; amino acid analyzer relocated to Cambridge, UK; Fluidics products shipping from Minneapolis using parallel build approach.
• Cost Savings: $3M savings in 2027, $4M thereafter; 75% of savings expected to flow to gross margin.
• Cash Flow: Inventory build for Project Viking expected to drop significantly post-Q1 2027, aiding cash generation improvements in 2027.
• Financing: Progress made on refinancing $10M term loan B with an asset-based revolver; interest savings and working capital flexibility anticipated upon announcement.
• Commercial Structure: Revamped team established dedicated key accounts group for top-tier pharma, CRO, and biotech customers.
• Scientific Advisory Board: Inaugural meeting held; quarterly meetings scheduled to guide technology roadmap.

Risks and Headwinds to Outlook:

• Product Mix: Higher sales volume of lower-margin legacy products, distribution channel mix, and China shipments are currently suppressing gross margins and EBITDA growth guidance.
• Operational Execution: Delays in Project Viking completion could impact expected 2027 cost savings and cash flow.
• Academic Funding: Weakness in U.S. and European academic funding remains a risk to future growth.
• Market Competition: Uncertainty regarding share gains against larger competitors (Thermo, Lonza) in the bioproduction sector until GMP launch.
• Regulatory/Policy: Future political decisions on NIH spending could impact demand, though not priced into current guidance.

Management Tone on the Future:

• Confidence: Management expresses confidence in the trajectory of the business for 2027, citing "sustainable" return to sales growth and disciplined operation.
• Guidance Changes: Reaffirmed top-line and margin targets for 2026 but lowered EBITDA growth guidance to reflect current product mix realities; outlook for 2027 emphasizes margin expansion post-consolidation.
• Sentiment: Positive on "industry tailwinds," "commercial momentum," and the alignment of innovation pipeline with new approach methodologies.

Miscellaneous:

• Stock Split: All per-share numbers retroactively reflect the 1-for-10 reverse stock split completed in March 2026.
• Stock Compensation: Elevated OPEX due to restored salaries, merit, and bonus potentials; normalization expected to improve leverage in 2027.
• Balance Sheet: Cash balance of $4.9 million; net debt $35.1 million; non-cash deferred financing amortization $0.3M/quarter; exit fee accruals $0.2M/quarter.